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ABSTRACT 
Cancer is a complex, robust disease with multiple redundant disease pathways which lead to tumor               
development, growth, and eventually even death. Despite known redundancies, cancer therapeutics continue to             
be developed against a single protein target. Initial disease regression occurs followed by relapse in a drug                 
resistant disease state. In response, combinational drug clinical trial targeting multiple pathways began, and              
have failed due to increased toxicity caused by adverse drug interactions. Development of a single drug that                 
differentially targets multiple disease pathways will result in a more potent therapeutic while inducing minimal               
toxicity. This was done computationally through in-lab software packages, like CANDOCK, designed to build              
novel therapeutics that selectively target user defined protein targets. Four protein targets (androgen receptor,              
estrogen receptor, glucocorticoid receptor, and peroxisome proliferator-activated receptor gamma) were chosen           
for their known involvement in bladder cancer proliferation and metastasis. Computationally designed            
compounds were then synthesized and screened for high potency in bladder cancer cell lines using the                
CellTiter-Blue cell viability assay. Several compounds decreased the cell viability and hindered growth in both               
mouse and two human bladder cancer cell lines (MB49, T24, and 5637 cell lines, respectively). In addition, some                  
potent compounds displayed decreased nitrous oxide production in RAW 264.7 cells, a mouse macrophage              
model, using a Griess assay. Thus showing that these compounds could decrease immunosuppression in the               
tumor microenvironment and slow cancer cell proliferation ​in vivo​. 
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